EPEvgenii A. Patrakhanov

Evgenii A. Patrakhanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evgenii A. Patrakhanov has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HAEE tetrapeptide as a promising neuroprotector: comparison with Piracetam in an experimental model of Alzheimer's disease

    by Evgenii A. Patrakhanov, Elеna V. Kuzubova, Nikita S. Zhunusov, Alexandra I. Radchenko, Vladislav Y. Kurdyukov, Anastasia R. Denisova, Alina A. Avramenko, Mikhail V. Pokrovskii

    Introduction: During the experiment, the effectiveness of tetrapeptide HAEE and the comparison drug Piracetam in correcting neurodegenerative disorders in Alzheimer's disease was investigated in a model of transgenic mice. Materials and Methods: transgenic mice of the APPswe/PS1dE9 (APP/PS1) line were used in the study. The animals were injected with HAEE and Piracetam, after which behavioral tests were performed (“Open Field”, “Light‑Dark Chamber”, “Novel Object Recognition”, “Barnes Maze”). Additionally, gene expression was analyzed using real‑time PCR. The histological study included staining of brain sections with Congo red, followed by counting amyloid plaques in the cortex and hippocampus. Results and Discussion: The administration of HAEE and Piracetam led to an improvement in cognitive performance, with both groups demonstrating memory recovery to the level of intact controls. Histological analysis showed an increase in the number of amyloid plaques in the positive control animals and a reduction in the therapeutic groups by an average of 40%. Gene expression analysis showed that HAEE and Piracetam modulate key molecular pathways associated with neuroplasticity, inflammation, and cellular survival. Changes in the expression of the Stat3, mTor, Vegfa, and Casp3 genes have been observed, reflecting the activation of compensatory neuroprotective mechanisms, as well as the relative stabilization of the pro‑inflammatory markers Il‑6 and Tnf‑a. Conclusion: HAEE tetrapeptide at a dosage of 50 mg per 1 kg and Piracetam at a dosage of 200 mg/kg have a comprehensive positive effect on cognitive functions, molecular and morphological parameters in Alzheimer’s disease. The results obtained in the animal model confirm its high potential as a promising neuroprotective agent, comparable to or superior to classical nootropic drugs.

  • Open Access

    Особенности кишечной микробиоты и методы ее исследования у лиц с различным уровнем физической активности

    by Валентина Кривко, Евгений Патраханов, Роман Аянка

    Введение. Кишечная микробиота играет ключевую роль в поддержании гомеостаза, иммунитета и метаболизма человека. Данные о её составе и функциях у лиц с разным уровнем физической активности противоречивы, а влияние спорта и диеты на микробные сообщества изучено недостаточно. Цель данного обзора – провести комплексный анализ таксономического состава и функций микробиоты кишечника, а также методов её исследования с акцентом на особенности микробиома профессиональных спортсменов. Материалы и методы. Проведён анализ и обобщение данных отечественной и зарубежной литературы, посвящённой таксономическому и функциональному профилю микробиоты профессиональных спортсменов, а также методам её изучения. Заключение. Регулярная физическая активность ассоциирована с повышением α-разнообразия кишечной микробиоты и увеличением численности таксонов, благоприятных для здоровья человека (Akkermansia muciniphila, Faecalibacterium prausnitzii, Veillonella atypica). Однако достоверная интерпретация этих данных ограничена в виду невозможности разделить влияние собственно физических нагрузок и диеты спортсменов, а также преобладанием поперечных исследований, основанных на секвенировании ампликонов гена 16S рРНК. Для оценки функционального потенциала микробных сообществ профессиональных спортсменов необходимы проспективные исследования с применением омиксных технологий и экспериментальных моделей, что позволит разработать стратегии поддержки кишечной экосистемы у лиц с разным уровнем физической активности.

  • Open Access

    Local Administration of pCMV-VEGF165 Plasmid Encoding VEGF Stimulates Tissue Regeneration after Cold Injury in Rats

    by O. V. Shcheblykina, D. A. Kostina, V. V. Arkhipov, E. A. Patrakhanov, A. A. Dolzhikov, V. V. Gureev, N. I. Zhernakova, O. A. Osipova, M. V. Pokrovskii

    INTRODUCTION. Frostbite is a common cold injury that is associated with high rates of disability and requires long and difficult treatment. A vascular endothelial growth factor (VEGF)-encoding pCMV-VEGF165 plasmid-based gene therapy product designed for therapeutic angiogenesis may be a promising tool to promote microcirculation recovery and accelerate lesion healing in local cold injury. This hypothesis needs to be tested in an experimental animal study.AIM. This study aimed to evaluate the efficacy of the pCMV-VEGF165 plasmid gene therapy product for the management of cold injury of a limb in rats.MATERIALS AND METHODS. The study included 42 mature female outbred white laboratory rats. A third to fourth-degree local cold injury was experimentally induced on the dorsal surface of the left hind paw by applying a neodymium magnet frozen in liquid nitrogen. The animals received periwound injections of the test product (super-coiled circular double-stranded plasmid deoxyribonucleic acid at a dose of 60 μg) and placebo (water for injections) on days 2 and 7 after frostbite modelling. The authors evaluated the general condition of the animals, the condition of the damaged paw, the wound area, the healing rate, the body mass, and, after planned euthanasia, the mass of the hind paws.RESULTS. Starting from day 7, the rats treated with the test product showed significantly faster tissue regeneration at the site of cold injury than the control animals. The mean wound surface area reduction in the test animals amounted to 47.36% [25.55; 55.45], whereas that in the control animals was 28.95±18.55% (pCONCLUSIONS. The pCMV-VEGF165 plasmid gene therapy product injected in the periwound area at a dose of 60 μg on days 2 and 7 after cold injury simulation in rats reduces damage, accelerates tissue regeneration under the scab, and expedites scarring.

  • Open Access

    Polymorphism in Genes Encoding HSP40 Family Proteins is Associated with Ischemic Stroke Risk and Brain Infarct Size: A Pilot Study

    by Ksenia A. Kobzeva, Denis E. Gurtovoy, Alexey V. Polonikov, Vladimir M. Pokrovsky, Evgeny A. Patrakhanov, Olga Y. Bushueva

    Background: Heat shock proteins (HSPs) play a critical role in the molecular mechanisms of ischemic stroke (IS). A possible role for HSP40 family proteins in atherosclerosis progression has already been revealed; however, to date, molecular genetic studies on the involvement of genes encoding proteins of the HSP40 family in IS have not yet been carried out. Aim: We sought to determine whether nine single nucleotide polymorphisms (SNPs) in genes encoding HSP40 family proteins (DNAJB1, DNAJB2, DNAJA1, DNAJA2, DNAJA3 and DNAJC7) are associated with the risk and clinical features of IS. Methods: Using TaqMan-based polymerase chain reaction (PCR) and the MassArray-4 system, DNA samples of 2551 Russians — 1306 IS patients and 1245 healthy individuals — were genotyped. Results: SNP rs2034598 DNAJA2 decreased the risk of IS exclusively in male patients (odds ratio = 0.81, 95% confidence interval 0.78–0.98, p = 0.028); rs7189628 DNAJA2 increased the brain infarct size (p = 0.04); and rs6500605 DNAJA3 lowered the age of onset of IS (p = 0.03). SNPs rs10448231 DNAJA1, rs7189628 DNAJA2, rs4926222 DNAJB1 and rs2034598 DNAJA2 were involved in the strongest epistatic interactions linked to IS; SNP rs10448231 DNAJA1 is characterised by the most essential mono-effect (2.96% of IS entropy); all of the top SNP–SNP interaction models included the pairwise combination rs7189628 DNAJA2×rs4926222 DNAJB1, which was found to be a key factor determining susceptibility to IS. In interactions with the studied SNPs, smoking was found to have multidirectional effects (synergism, antagonism or additive effect) and the strongest mono-effect (3.47% of IS entropy), exceeding the mono-effects of rs6500605 DNAJA3, rs10448231 DNAJA1, rs2034598 DNAJA2, rs7189628 DNAJA2 and rs4926222 DNAJB1, involved in the best G×E models and determining 0.03%–0.73% of IS entropy. Conclusions: We are the first to discover polymorphisms in genes encoding HSP40 family proteins as a major risk factor for IS and its clinical manifestations. The comprehensive bioinformatics analysis revealed molecular mechanisms, underscoring their significance in the pathogenesis of IS, primarily reflecting the regulation of heat stress, proteostasis and cellular signalling.


  • Open Access

    Effectiveness of the tetrapeptide HAEE: an innovative approach to Alzheimer's treatment in experimentation

    by Evgenii A. Patrakhanov

    Introduction: Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized by a progressive decline in cognitive functions. According to the “Alzheimer’s Disease International”, there were 36 million reported cases of AD worldwide in 2009, with projections suggesting an increase to 66 million by 2030 and 115 million by 2050. Materials and Methods: The study was conducted on three experimental groups consisting of male APPswe/PS1dE9/Blg mice on a mixed genetic background with C57Bl6/Chg animals. Each group included 10 mice. At the baseline (point 0), peptides and drugs were administered to two groups of animals aged 6 months. The treatments were given circadianly every 48 hours without breaks for one month. Subsequently, at point 1 of the experiment, half of the group (n=5) was selected for further histological analysis of the brain. The remaining half did not receive any treatments for one month before undergoing histological examination. Statistical significance between experimental and control groups was assessed using an unpaired Student’s t-test at p<0.05. Results and Discussion: Histological analysis indicated the efficacy of the tetrapeptide HAEE at a dosage of 50 mg per kg of mouse weight, showing a significant reduction in amyloid plaques in the cerebral cortex and hippocampus of the mice. Conclusion: The study supports the proposed hypotheses and suggests further investigation into additional drug groups recommended for Alzheimer’s treatment for comparative studies.


  • Open Access

    Obesity and Environmental Risk Factors Significantly Modify the Association between Ischemic Stroke and the Hero Chaperone C19orf53

    by Irina Shilenok, Ksenia Kobzeva, Alexey Deykin, Vladimir Pokrovsky, Evgeny Patrakhanov, Olga Bushueva

    The unique chaperone-like properties of C19orf53, discovered in 2020 as a “hero” protein, make it an intriguing subject for research in relation to ischemic stroke (IS). Our pilot study aimed to investigate whether C19orf53 SNPs are associated with IS. DNA samples from 2138 Russian subjects (947 IS and 1308 controls) were genotyped for 7 C19orf53 SNPs using probe-based PCR. Dominant (D), recessive (R), and log-additive (A) regression models in relation to the effect alleles (EA) were used to interpret associations. An increased risk of IS was associated with rs10104 (EA G; Pbonf(R) = 0.0009; Pbonf(A) = 0.0004), rs11666524 (EA A; Pbonf(R) = 0.003; Pbonf(A) = 0.02), rs346158 (EA C; Pbonf(R) = 0.006; Pbonf(A) = 0.045), and rs2277947 (EA A; Pbonf(R) = 0.002; Pbonf(A) = 0.01) in patients with obesity; with rs11666524 (EA A; Pbonf(R) = 0.02), rs346157 (EA G; Pbonf(R) = 0.036), rs346158 (EA C; Pbonf(R) = 0.005), and rs2277947 (EA A; Pbonf(R) = 0.02) in patients with low fruit and vegetable intake; and with rs10104 (EA G; Pbonf(R) = 0.03) and rs11666524 (EA A; Pbonf(R) = 0.048) in patients with low physical activity. In conclusion, our pilot study provides comprehensive genetic and bioinformatic evidence of the involvement of C19orf53 in IS risk.


  • P2X3 receptor blockade alters cellular respiration of primary mixed hippocampal neuronal culture

    by A.S. Zelentsova, E.A. Patrakhanov, V.M. Pokrovsky, V.S. Shmigerova, E.V. Kuzubova, A.V. Deykin, M.YU. Skorkina

    Objective. To study mitochondrial respiration of primary mixed hippocampal neuronal culture under pharmacological blockade of purine P2X3 receptor. Material and methods. This experiment was performed on 2-day-old CD-1 mice obtained from sexually mature females. Primary mixed hippocampal neuronal culture was harvested and seeded into Cell Culture Manipulates (Agilent, USA) (4∙105 in 80 μl). P2X3 receptor blockade was performed by 5-(five-(5-iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2.4-diamine monochloride salt with final concentration 12 nM. We measured basal cellular respiration on the 1st, 5th, 8th, 11th and 14th days of differentiation (Agilent cell metabolism analyzer). Energy phenotype of neurons was assessed on the 14th day of differentiation. Metabolic maps were plotted using Nova 1.3 software (USA). Results. In most cells, P2X3 receptor blockade was followed by higher cellular respiration on the 1st day of differentiation by 18.8% (p<0.05), 39% after 5 days, 32% after 8 days, 24% after 11 days and 19% after 14 days (p<0.05) compared to the control group. In few cells, we observed lower oxygen consumption by 56% after 5 days (p<0.05), 32% after 8 days (p<0.05), 24% after 11 days (p<0.05) and 32% after 14 days (p<0.05) compared to the control group. In case of P2X3 receptor blockade in hippocampal neuronal culture, mitochondrial respiration switched to energy phenotype through glycolytic component. Conclusion. Our findings complement modern data on the role of P2X3 receptor in mitochondrial physiology. Moreover, one can use these data in searching for pharmacological strategies aimed at control of mitochondrial function as therapeutic interventions for pain syndromes.


  • Open Access

    Neuroprotective properties of Na+/H+-exchanger isoform-1 inhibitor in experimental POAG

    by Anna S. Pobeda, Alexander A. Spasov, Olga N. Zhukovskaya, Kristina V. Shchurovskaya, Nikolai V. Solovev, Valentina A. Kulikovskaya, Vladimir M. Pokrovsky, Evgeny A. Patrakhanov, Anastasia V. Turpakova, Anna I. Ustinova

    Introduction: Worldwide glaucoma is the leading cause of irreversible vision loss. The processes associated with the loss of retinal ganglion cells are multifactorial and have much in common with neurodegenerative diseases. Therefore the search for means to prevent the death of retinal neurons is an important task of modern pharmacology. Materials and Methods: The study was conducted on male Wistar rats. Glaucoma was modeled by injecting a 1% solution of hyaluronic acid into the anterior chamber of the eye. The IOP level was recorded on the 0th, 63rd and 73rd days of the experiment. The effectiveness of the drugs was evaluated based on the results of ophthalmoscopy, electroretinography, followed by the determination of gene expression. Results and Discussion: In the group with RU-1355 correction, the fundus picture improved; the index in the group was 18.0% lower compared to the model. The introduction of the RU-1355 compound provided an increase in the a-wave amplitude by 18.1%, and b-wave amplitude by 39.0% relative to the group with pathology. The most pronounced effect was observed on the expression level of BDNF, Bcl-2, Caspase 3 and NF-κB p65, which indicates that the compound has the capacity to influence the slowdown of the apoptosis process through an increase in the neurotrophic factor and the anti-apoptotic factor Bcl-2. Conclusion: RU-1355 has neuroprotective properties, which was expressed by a decrease in ophthalmoscopic manifestations, preservation of the b-wave amplitude of the electroretinogram and the influence on gene expression of factors involved in apoptosis and neuroprotection. Based on the pharmacological activity of the RU-1355 compound in relation to POAG, further study of its action against other retinal diseases is promising.

  • Open Access

    DEVELOPMENT OF MURINE STEM CELLS WITH CONDITIONAL KNOCKOUT OF HUMANIZED SNCA GENE

    by E. A. Patrakhanov, В. М. Покровский, A. Yu. Karagodina, A. M. Krayushkina, N. S. Zhunusov, A. V. Deykin, M. V. Korokin, М. В. Покровский, O. B. Altukhova

    α-synuclein is one of the key molecular links in the pathogenesis of Parkinson’s disease. The accumulated data indicate that pathogenic mutations in theSncagene are associated with the development of neurodegenerative brain damage, indicating the relevance of studying the synuclein neurobiological role.The aimof the study was to create a genetically modified clone of mouse stem cells with a conditional knockout of humanized α-synuclein, which can be used for the reinjection into mouse blastocysts, as well as for basic and appliedin vitroresearch in the field of pathophysiology and neuropharmacology.Materials and methods.To create mouse stem cells with a conditional knockout of the humanizedSncagene, a previously obtained clone with the firstSncaexon flanked by LoxP sites, was used. The CRISPR/Cas9-mediated homologous recombination system with donor DNA oligonucleotides of the human sites of the corresponding gene sites was used to humanize the fourth and fifth exons. Cas9 nuclease, single guide RNA, and donor DNA were transfected into mouse cells.Results.An approach to obtaining clones of mouse genetically modified stem cells expressing pathological humanized α-synuclein, has been proposed and implemented. The resulting clones were plated on Petri dishes for propagation and a further genetic analysis. Clone 126-2F4 was found out carrying the necessary genetic modifications. The results obtained are fundamentally important not only for understanding the development of the pathological process in α-synucleinopathies, but which is more important, for the development of new therapeutic approaches that will stop the extension of the human α-synuclein aggregation pathology throughout the nervous system, and the validation of these approaches in preclinical trials.Conclusion.As a result of the study, a strategy for CRISPR/Cas9-assisted homologous recombination in the genome of mouse embryonic stem cells has been developed to create a fully humanizedSncagene encoding α-synuclein, and the clone genome of mouse embryonic stem cells has been edited using a CRISPR technology. The RNA and DNA oligonucleotides necessary for the creation of RNP complexes that carry out a directed homologous recombination in theSncalocus of the mouse genome have been synthesized. The developed cell clone can serve to create a line of genetically modified mice that serve as a test system for pathophysiological and neuropharmacological studies associated with synucleinopathies. Herewith, before the induction of the Cre-dependent recombination, this line is a representative model for studying a biological role of mutantSnca. At the same time, after a Cre-dependent knockout activation, it is possible to imitate the pharmacological inhibition of α-synuclein, which is of particular interest for applied research in neuropharmacology.